Loading cancer entity…
Loading cancer entity…
Clinical trials
10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,641)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03288493 | P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 105 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT04762160 | SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma | terminated | Phase 2 | 5 | Epizyme, Inc.INDUSTRY | 1 | Mar 25, 2024 | clinicaltrials |
| NCT02451111 | Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma | terminated | Phase 2 | 190 | Swiss Cancer InstituteOTHER | 6 | Mar 13, 2024 | clinicaltrials |
| NCT02700841 | Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation | terminated | Phase 2 | 8 | University of NebraskaOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06160609 | Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM | terminated | Phase 1 / Phase 2 | 9 | GlaxoSmithKlineINDUSTRY | 3 | Mar 12, 2024 | clinicaltrials |
| NCT02282358 | Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | terminated | Phase 1 / Phase 2 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04509466 | Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL | terminated | Phase 1 / Phase 2 | 41 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT03357224 | PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)(PARCT) | terminated | Phase 2 | 26 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Feb 22, 2024 | clinicaltrials |
| NCT05611853 | Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | terminated | Phase 1 / Phase 2 | 9 | BioNova Pharmaceuticals (Shanghai) LTD.INDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT03684694 | Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma | terminated | Phase 1 / Phase 2 | 136 | ADC Therapeutics S.A.INDUSTRY | 6 | Feb 6, 2024 | clinicaltrials |
| NCT04465760 | Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy | terminated | Phase 2 | 9 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03495713 | Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS | terminated | Phase 2 | 7 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT03458728 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | terminated | Phase 1 / Phase 2 | 31 | BayerINDUSTRY | 1 | Dec 4, 2023 | clinicaltrials |
| NCT03572634 | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL | terminated | Phase 1 / Phase 2 | 3 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 9, 2023 | clinicaltrials |
| NCT02188368 | Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients | terminated | Phase 2 | 45 | OncotherapeuticsINDUSTRY | 1 | Nov 3, 2023 | clinicaltrials |
| NCT02294357 | Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib | terminated | Phase 2 | 45 | OncotherapeuticsINDUSTRY | 1 | Nov 1, 2023 | clinicaltrials |
| NCT02763384 | BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma | terminated | Phase 2 | 12 | Washington University School of MedicineOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03733691 | Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | terminated | Phase 2 | 19 | OncotherapeuticsINDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
| NCT04843579 | Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients(ClaSPd) | terminated | Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT03679624 | Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia | terminated | Phase 2 | 1 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04699461 | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma(LOTIS-6) | terminated | Phase 2 | 6 | ADC Therapeutics S.A.INDUSTRY | 10 | Oct 23, 2023 | clinicaltrials |
| NCT03947255 | A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma | terminated | Phase 2 | 12 | Seagen Inc.INDUSTRY | 1 | Oct 13, 2023 | clinicaltrials |
| NCT03093831 | Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma | terminated | Phase 2 | 5 | National Cancer Centre, SingaporeOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT02957019 | A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | terminated | Phase 1 / Phase 2 | 6 | Philogen S.p.A.INDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
| NCT01177683 | Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma | terminated | Phase 1 / Phase 2 | 32 | Sherif Farag, MB, BSOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT02065869 | Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 187 | Bellicum PharmaceuticalsINDUSTRY | 2 | Sep 29, 2023 | clinicaltrials |
| NCT02391545 | A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO) | terminated | Phase 1 / Phase 2 | 55 | SecuraBioINDUSTRY | 6 | Sep 28, 2023 | clinicaltrials |
| NCT04205240 | Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma | terminated | Phase 2 | 1 | Srinivas DevarakondaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04692155 | Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)(CHOP U2) | terminated | Phase 1 / Phase 2 | 1 | University of Alabama at BirminghamOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03733249 | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | terminated | Phase 1 / Phase 2 | 187 | Bellicum PharmaceuticalsINDUSTRY | 1 | Sep 26, 2023 | clinicaltrials |
| NCT00006478 | Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma | terminated | Phase 2 | 19 | University of NebraskaOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT03201250 | Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | University of NebraskaOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | terminated | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT02906332 | Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) | terminated | Phase 2 | 12 | Hackensack Meridian HealthOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT04119336 | Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma | terminated | Phase 2 | 2 | Andrew Yee, MDOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT03229382 | Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse(OPERA-PLRG10) | terminated | Phase 2 | 1 | Polish Lymphoma Research GroupNETWORK | 1 | Aug 16, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT03828448 | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma | terminated | Phase 2 | 34 | TG Therapeutics, Inc.INDUSTRY | 1 | Jul 24, 2023 | clinicaltrials |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT00074165 | Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen | terminated | Phase 2 | 17 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT00335140 | Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma | terminated | Phase 2 | 26 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 3, 2023 | clinicaltrials |
| NCT00060346 | Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia | terminated | Phase 2 | 16 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00070291 | Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma | terminated | Phase 2 | 4 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01390584 | Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma | terminated | Phase 2 | 6 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00057954 | Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma | terminated | Phase 2 | 6 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT01307605 | Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma | terminated | Phase 2 | 154 | Swiss Cancer InstituteOTHER | 3 | Jun 27, 2023 | clinicaltrials |
| NCT02794246 | CART-19 Post-ASCT for Multiple Myeloma | terminated | Phase 2 | 6 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03782064 | Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma | terminated | Phase 2 | 5 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01378871 | A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma | terminated | Phase 2 | 1 | Amit VermaOTHER | 1 | Jun 9, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Mar 28, 2024source: clinicaltrials